Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression

Tingting Zhang, Elaine Kingwell, Hilda J. I. De Jong, Feng Zhu, Yinshan Zhao, Robert Carruthers, John Petkau, Paul Gustafson, Joel Oger, Helen Tremlett

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1150-1159
JournalPharmacoepidemiology and Drug Safety
Volume25
Issue number10
DOIs
Publication statusPublished - Oct 2016

Keywords

  • multiple sclerosis
  • disability progression
  • SSRIs
  • effectiveness
  • population-based data
  • pharmacoepidemiology

Cite this

Zhang, T., Kingwell, E., De Jong, H. J. I., Zhu, F., Zhao, Y., Carruthers, R., Petkau, J., Gustafson, P., Oger, J., & Tremlett, H. (2016). Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression. Pharmacoepidemiology and Drug Safety, 25(10), 1150-1159. https://doi.org/10.1002/pds.4031